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MISSING THE “TARGET”: 
PREVENTING THE UNJUST 
INCLUSION OF VULNERABLE 
CHILDREN FOR MEDICAL 
RESEARCH STUDIES 
Ruqaiijah Yearby† 
I. INTRODUCTION 
Nearly everyone has experienced a burn and the resulting pain. Now imagine that 
you suffer a third-degree radiation burn that injures all the layers of your skin as well 
as the tissue, causing you extreme pain. . The burn turns your skin white, cherry red, or 
black and may produce blisters that are dry, hard, and leathery-looking. The burn can 
also be seen on the surface of your lungs and gastrointestinal tract. If the burn is big 
enough you will need skin grafts and surgery to replace the skin and tissue that will 
never grow back, as well as treatment to prevent infection. Assumedly, no human 
being would intentionally cause another human being to experience this type of pain 
and suffering. However, U.S. researchers did. Researchers at the Medical College of 
Virginia conducted radiation tests on healthy African American children, as young as 6 
months old, deliberately causing third-degree burns to their skin.1 The tests not only 
damaged the skin of these children, causing them extreme pain, but it also required 
surgery and skin grafts.2 
Although the central purpose of medical research on children is to “generate new 
knowledge” that can improve children’s health, research “can never take precedence 
                                                 
† Oliver C. Schroeder Jr. Distinguished Research Scholar and Professor of Law, Case Western Reserve 
University, School of Law, B.A. (Honors Biology), University of Michigan, 1996; J.D., Georgetown 
University Law Center, 2000; M.P.H., Johns Hopkins School of Public Health, 2000. I would like to thank 
Ifeoma Ajunwa, Deleso Alford, Ayesha Bell Hardaway, Devonya Havis, Cynthia Ho, Laura McNally-
Levine, Teresa Miller, Rebecca Redwood, and L. Song Richardson for their insightful comments. 
Additionally, I would also like to thank my outstanding research assistants, Samantha Malusky, Nadia 
Chaudhry, Maureen Polen, and Di Zhang. A draft of this paper was presented at the Oxford Global Health 
and Bioethics International Conference in Oxford, England and the Lutie A. Lytle Black Female Faculty 
Writing Workshop. 
1 HARRIET WASHINGTON, MEDICAL APARTHEID 236-37 (2007) (discussing a Medical College of 
Virginia experiment to determine “whether radiation inflicted different degrees of damage on the skins of 
black people than on that of whites”). 
2 See id.  
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over the rights and interests of” children serving as research subjects.3 Unfortunately, 
medical research has too often taken precedence over the rights and interests of 
children, which is why many researchers and bioethicists have characterized the 
history of medical research on children as a history of child abuse.4 Usually, the debate 
regarding the use of children in medical research studies has centered on questions 
regarding the ethical principles of autonomy (informed consent)5 and beneficence (the 
best interest of the child based on a benefit risk analysis).6 The debate has rarely 
focused on the justice principle.7 
My article begins to fill this void by critically analyzing medical research studies 
conducted on children by discussing the requirements of the justice principle. The 
justice principle, used to determine who will serve as a research subject,8 is the most 
significant ethical principle governing medical research studies because the first thing 
that researchers must consider when designing their study is subject selection. Once it 
is decided who will serve as a research subject, the researcher can determine whether 
the study complies with the requirements of autonomy and beneficence.  
When selecting research subjects, the justice principle prohibits targeting. 
Targeting is the systematic selection of research subjects who are from vulnerable 
populations, such as racial minorities, children, and the economically disadvantaged, 
“because of their easy availability, their compromised position, or their manipulability, 
rather than for reasons directly related to the problem being studied.”9 Additionally, 
even if the research is directly related to a condition suffered by the vulnerable 
population, researchers should not use these populations as research subjects if they 
are already overburdened due to lack of access to essential goods, such as food and 
housing. Consequently, research subjects should be chosen according to an order of 
                                                 
3 Declaration of Helsinki, WORLD MED. ASS’N (2016), http://www.wma.net/en/30publications/ 
10policies/b3/ [http://perma.cc/HNL2-JSZ9] (last amended in October 2013). 
4 Susan E. Lederer & Michael A. Grodin, Historical Overview: Pediatric Experimentation, in 
CHILDREN AS RESEARCH SUBJECTS: SCIENCE, ETHICS, AND LAW 18-19 (Michael A. Grodin & Leonard H. 
Glantz eds., 1994). 
5 45 C.F.R. § 46.408 (2015). For a detailed discussion regarding the balance between the need for 
medical research studies on children and the need for informed consent, see Additional Protections for 
Children Involved as Subjects in Research, 48 Fed. Reg. 9814 (Mar. 8, 1983); Fed. Reg. 31,786 (July 21, 
1978); National Institutes of HEALTH, NIH Policy And Guidelines On The Inclusion Of Children As 
Participants In Research Involving Human Subjects (Mar. 6, 1998), http://grants.nih.gov/ 
grants/guide/notice-files/not98-024.html [https://perma.cc/53WP-LVQZ]; NAT'L COMM'N FOR THE 
PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAV. RES., PUBL’N NO. (OS) 77-0004, REPORT 
AND RECOMMENDATIONS: RESEARCH INVOLVING CHILDREN, PASSIM (1977). Paul Ramsey and Richard 
McCormick provided the most influential discussion regarding 2 (arguing that “any non-therapeutic research 
on children was absolutely unethical—even with parental approval”); Richard A. McCormick, 
Experimentation in Children: Sharing in Sociality, 6 HASTING CTR. REP. 41, 42 (1976) (arguing that 
children may participate in medical research studies with parental consent if it would benefit the child and is 
a “reasonable presumption of the child’s wishes”). 
6 45 C.F.R. §§ 46.404-46.407 (2010); NAT’L INSTS. OF HEALTH, supra note 5; NAT'L COMM'N FOR THE 
PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAV. RES., supra note 5. See also, Loretta 
Kopelman, Children as Research Subjects: Moral Disputes, Regulatory Guidance, and Recent Court 
Decisions, 73 MOUNT SINAI J. MED. 596 (2006); Michelle Oberman & Joel Frader, Dying Children and 
Medical Research: Access to Clinical Trials as Benefit and Burden, 29 AM. J.L. & MED. 301 (2003). 
7 45 C.F.R. § 46.111(a)(3) (2015) (prohibiting targeting children for use in medical research studies).  
8 The Belmont Report, 76 Fed. Reg. 23,192, 23,194 (Apr. 18, 1979). 
9 Id. The justice principle also requires that if vulnerable populations are used in medical research 
studies then the benefits of the research must be distributed to those vulnerable populations. See id. I discuss 
the justice principle’s requirement that the populations that participate in medical research studies must be 
the populations that benefit from the research in my forthcoming article entitled, Exploitation in Medical 
Research Forty Years After the Tuskegee Syphilis Study, 67 CASE W. RES. UNIV. L. REV. (2017) 
(forthcoming). 
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preference of subjects for research: the economically advantaged before the 
economically disadvantaged, the majority before minorities, and adults before 
children. 
Notwithstanding the Justice Principle, researchers continue to target children for 
medical research studies. Since the late 1700s, children have repeatedly been targeted 
for participation in medical research studies because they were readily accessible and 
easy to manipulate.10 Using economically disadvantaged minority children as an 
example of the harm all children suffer when targeted for medical research studies, I 
argue that the justice principle must be redefined and new safeguards must be 
implemented to protect all child participants. Specifically, Section II provides a 
descriptive overview of the purpose and structure of medical research studies, as well 
as a brief history of medical research studies that targeted economically disadvantaged 
minority children. Section III examines the parameters of the justice principle and 
further defines what constitutes targeting. Section IV discusses the problems with the 
enforcement of the justice principle and provides examples of medical research studies 
that targeted and harmed economically disadvantaged minority children in the United 
States and abroad as a result of these problems.  
In Section V, I propose several ways to end targeting in the United States and 
abroad. First, the justice principle must be redefined to mean equity in participation. 
Equity in participation would require researchers to use non-disadvantaged children as 
research subjects unless the study is a priority to and does not overburden 
economically disadvantaged minority children. To measure whether equity in 
participation is met, researchers should be required to use the proposed Vulnerability 
and Equity Impact Assessment (VEIA) tool,11 to determine whether the selection of 
children from particular groups as research subjects violates the redefined justice 
principle. Finally, I suggest the creation of a Board of Children to review all medical 
research studies regulated by the United States that use children as research subjects. If 
all of these recommendations are implemented, it will prevent economically 
disadvantaged minority children from being targeted in medical research studies for 
the benefit of an unworthy society.  
II. MEDICAL RESEARCH STUDIES INVOLVING CHILDREN: THE 
STRUCTURE AND HISTORY 
There are two types of medical research studies involving human subjects: Non-
therapeutic and Therapeutic.12 Regardless of the type of medical research study, all 
                                                 
10 Leonard Glantz, Research with Children, 24 AM. J.L. & MED 213, 215-18 (1998); LEDERER & 
GRODIN, supra note 4, at 12, 19. Children have also been exploited in medical research studies for 
conditions that were not limited to children. Id. Moreover, many medical research studies conducted on 
children produce minimal scientific benefits in comparison to their costs and are stigmatizing. See, e.g., 
Solomon R. Benatar, Global Health and Justice: Re-Examining Our Values, 27 BIOETHICS 297, 301-02 
(2013); Iain Chalmers & Paul Glasziou, Avoidable Waste in the Production and Reporting of Research 
Evidence, 374 LANCET 86 (2009); WASHINGTON, supra note 1, at 271-96; LAINIE ROSS, CHILDREN IN 
MEDICAL RESEARCH: ACCESS VERSUS PROTECTION 48-56 (2006).  
11 The Vulnerability and Equity Impact Assessment tool is based on the Health Equity Impact 
Assessment tool. For a description and evaluation of the Health Equity Impact Assessment tool see 
REBECCA HABER, HEALTH EQUITY IMPACT ASSESSMENT: A PRIMER (Wellesley Institute 2010) and Rainer 
Fehr, Environmental Health Impact Assessment, Evaluation of a Ten-Step Model, 10 EPIDEMIOLOGY 618 
(1999) (analyzing various ways to assess health impacts). 
12 Declaration of Helsinki (1964), 313 BRIT. MED. J. 1448, 1448 (1996) (distinguishing between 
research “in which the aim is essentially diagnostic or therapeutic for a patient” and that which “is purely 
scientific and without implying direct diagnostic or therapeutic value to the person subjected”). 
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studies using children entail risk of psychological and physical harm, as well as the 
possibility of stigma. In fact, countless children have suffered harm as a result of study 
participation, often without any benefit in return.13 Economically disadvantaged14 
minority children have been and continue to be overrepresented in medical research 
studies.15 
A. STRUCTURE OF MEDICAL RESEARCH STUDIES INVOLVING HUMAN SUBJECTS 
A non-therapeutic medical research study is conducted to obtain generalizable 
scientific knowledge.16 This research is done to learn more “about the subjects' 
disorder or condition which is of vital importance for the understanding or 
amelioration of the subjects' disorder or condition.”17 An example of non-therapeutic 
research is a study to ascertain the effects of household pesticide use on children’s 
health.18  
A therapeutic medical research study tests a vaccine, drug, or medical device for 
the treatment of a disease.19 An example of a therapeutic medical research study is the 
testing of HIV/AIDS drugs. There are five Phases of therapeutic medical research 
studies: Phase 0, I, II, III, and IV.20 Using drug medical research studies as an 
example, each Phase is discussed below. 
In a Phase 0 drug study, research is conducted using at most ten people and 
involves the administration of small doses of an experimental drug over a short period 
of time to determine if there is any pharmacological effect.21 The purpose of the study 
is to evaluate whether there is any effect in humans, before undertaking Phase I and II 
drug studies.22 Unlike Phase I drug studies, there is no therapeutic intent and little to 
no toxic effect in a Phase 0 drug study, which is primarily done for cancer drugs and 
therapies.23 
                                                 
13 Glantz, supra note 10, at 215-18. See also Lederer & Grodin, supra note 4, at 12, 19.  
14 Throughout the article, I use the term “economically disadvantaged” to discuss children who lack 
access to essential goods such as food, housing, and health care. Although the term can be over inclusive, for 
clarity, I have used the word accepted in the medical research community. For more discussion, see Carol 
Levine, Changing Views of Justice after Belmont: AIDS and the Inclusion of “Vulnerable” Subjects, in THE 
ETHICS OF RESEARCH INVOLVING HUMAN SUBJECTS: FACING THE 21ST CENTURY 105-24 (1996). 
15 See, e.g., WASHINGTON, supra note 1, at 271-96, ROSS, supra note 10, at 48; Vernellia Randall, 
Slavery, Segregation and Racism: Trusting the Health Care System Ain’t Always Easy! An African American 
Perspective on Bioethics, 15 ST. LOUIS U. PUB. L. REV. 191, 199 (1996).  
16 Declaration of Helsinki (1964), supra note 12. Children are allowed to participate in these studies 
where they present more than minimal risk to the subjects only if “[t]he risk represents a minor increase over 
minimal risk” and “[t]he intervention or procedure presents experiences to subjects that are reasonably 
commensurate with those inherent in their actual or expected medical, dental, psychological, social, or 
educational situations.” 45 C.F.R. § 46.406 (2015). 
17 45 C.F.R. § 46.406. 
18 For an example of one such study, see Jack K. Leiss & David A. Savitz, Home Pesticide Use and 
Childhood Cancer: A Case-Control Study, 85 AM. J. PUB. HEALTH 249 (1995).  
19 Declaration of Helsinki (1964), supra note 12.  
20 NAT’L INSTS. OF HEALTH, Glossary of Common Site Terms, CLINICALTRIALS.GOV, 
http://clinicaltrials.gov/ct2/info/glossary#Phasel (Feb. 2016) [https://perma.cc/V82C-BULR] (describing the 
five phases under the definition of “Phase”).  
21 Patient and Caregiver Resources: Phases of Clinical Trials, NAT’L COMPREHENSIVE CANCER 
NETWORK (2016), https://www.nccn.org/patients/resources/clinical_trials/phases.aspx [https://perma.cc/ 
WE4Q-WRP5].  
22 Id.  
23 Phases of Clinical Trials, CANCER RESEARCH U.K., (Oct. 21, 2015), http://www.cancerresearch 
uk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/phases-of-clinical-trials [https://perma.cc/ 
46RB-MAVZ].  
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In a Phase I drug study, research is conducted using a small number of subjects, 
less than 100 people, to obtain information regarding the safety and efficacy of the 
candidate drug on human subjects.24 Phase II studies obtain information from several 
hundred subjects regarding the subjects’ immune system’s response, the efficacy of the 
drug on different populations, and the effect of different doses on the population.25  
After preliminary evidence has been obtained suggesting effectiveness of the 
drug, a Phase III drug study is conducted “to gather additional information to evaluate 
the overall benefit-risk relationship of the drug and provide an adequate basis for 
physician labeling.”26 Researchers determine the efficacy of the drug in preventing the 
disease by following several thousand subjects.27 This is the last phase before the drug 
is marketed and distributed.28 Phase IV is the final step in drug studies.29 It includes 
“[p]ost-marketing . . . studies to delineate additional information about the drug's risks, 
benefits, and optimal use.”30 
The main difference between each Phase is the purpose of the study and the 
benefit. In Phase 0, I, and II studies, the goal is primarily the attainment of scientific 
knowledge, whereas in Phase III and IV studies, the goal is treatment.31 Many patients, 
physicians, and scholars often misunderstand the difference between research and 
therapy.32 Although there is no potential for a benefit in Phase 0, I, and II medical 
research studies, many patients, providers, and even researchers believe that 
enrollment in these studies is beneficial for the patient because the patient will receive 
treatment.33 This therapeutic misconception is used to justify the targeting of 
vulnerable research subjects, such as economically disadvantaged minority children, 
for participation in medical research studies.34  
B. EASILY MANIPULATED SUBJECTS: A BRIEF HISTORY OF TARGETING 
Although the definitions seem clear, ascertaining whether a study is non-
therapeutic or therapeutic can be difficult because both studies may potentially benefit 
society through either generalizable knowledge or direct treatment. Nevertheless, no 
matter whether the study is non-therapeutic or therapeutic, some researchers have 
targeted economically disadvantaged minority children for use in medical research 
studies, causing lifelong disability and/or death.35  
                                                 
24 Step 3: Clinical Research, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ForPatients/ 
Approvals/Drugs/ucm405622.htm (May 19, 2016) [https://perma.cc/N7PJ-VDAK]. 
25 Id.   
26 NAT’L INSTS. OF HEALTH, supra note 20.  
27 U.S. FOOD & DRUG ADMIN., supra note 24.  
28 See id.  
29 Id.  
30 21 C.F.R. § 312.85 (2016). See also Leslie Pickering Francis, Legitimate Expectations, 
Unreasonable Beliefs, and Legally Mandated Coverage of Experimental Therapy, 1 IND. HEALTH L. REV. 
215, 228 (2004) (“Phase IV trials undertake continued collection of data after a new drug is given marketing 
approval based on data from earlier trials. The goal of Phase IV is to collect data on an ongoing basis as an 
approved therapy becomes employed in the general population of patients in need of treatment. Distribution 
of a therapy into the general population of patients, outside the research context, may reveal quite different 
aspects of the therapy's risks and benefits.”).  
31 See Francis, supra note 30, at 228.  
32 Oberman & Frader, supra note 6, at 308-10. 
33 Francis, supra note 30, at 228-29. 
34 Oberman & Frader, supra note 6, at 308-10. 
35 WASHINGTON, supra note 1, at 271-96; Rupali Ghandhi, Research Involving Children: Regulations, 
Review Boards and Reform, 8 J. HEALTH CARE L. & POL’Y 264, 264-65 (2005); Oberman & Frader, supra 
note 6, at 308-10; Glantz supra note 10, at 215-17; Randall, supra note 15, at 199; Lederer & Grodin, supra 
note 4, at 19. 
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Between 1936 and 1960, psychiatrists and neurosurgeons conducted lobotomies 
on healthy African American boys as young as five years old that obliterated their 
thought ability and personality.36 The psychiatrists and neurosurgeons used crude tools 
such as the icepickalon.37 Inserting the tools into the boys’ brains, the researchers 
“blindly swept [the tools] back and forth . . . cutting all the connecting nerves,” 
removing any chance for the once healthy boys to lead a normal life.38 From 1949 to 
1960, the Medical College of Virginia conducted radiation tests on healthy African 
American children, as young as six months old, deliberately causing third-degree burns 
to their skin.39 In 1956, seventeen healthy African American infants were deprived of 
an essential nutrient, which researchers knew the body could not survive without.40 
Ten of the seventeen suffered severe complications, in order for scientists to determine 
if canned milk caused skin rash, diarrhea, or slow weight gain.41 Notwithstanding the 
complications, the study was repeated with 428 infants and seven of the infants died.42 
The U.S. Atomic Energy Commission (AEC) “irradiated 235 African American 
newborns from 1953 to 1954 in various hospitals across the nation” for no recorded 
therapeutic purpose since the infants were healthy.43 Between 1960 and 1970, the AEC 
sponsored a study in which radioactive material was added to the oatmeal of thirty 
healthy orphans, some of which were African American.44 The government obtained 
the bodies of the research participants who died to measure the levels of radioactivity 
and biological damage.45  
These are just a few examples of the targeting of economically disadvantaged 
minority children in medical research studies for the benefit of society. The children 
who participated in these studies were chosen because they were readily accessible and 
in a compromised position, not because they were particularly affected by the 
condition being studied. These historical abuses were the foundation for the 
application of social justice to medical research studies and the protection of 
vulnerable populations, particularly economically disadvantaged minority children, 
from exploitation.46 
III. THE JUSTICE PRINCIPLE: SOCIAL JUSTICE IN MEDICAL RESEARCH 
STUDIES 
The concept of social justice has been applied in the allocation of societal benefits 
and burdens, such as “punishment, taxation and political representation.”47 Before 
1979, most scholars, bioethicists, and researchers did not view social justice as 
                                                 
36 WASHINGTON, supra note 1, at 284. 
37 Id.  
38 Id.  
39 Id. at 236-37. This is the example referenced in the Introduction of this article. 
40 Id. at 294. 
41 Globe Reports Research Team Deprived Infants of Essential Nutrient, LEWISTON EVENING JOURNAL 
(Mar. 29, 1973), https://news.google.com/newspapers?id=oJggAAAAIBAJ&sjid=mmgFAAAAIBAJ&pg= 
1205%2C3872215 [https://perma.cc/UQ6T-LNYB]. 
42 WASHINGTON, supra note 1, at 294 
43 Id. at 238-39.  
44 Id. at 233. 
45 Id.  
46 Randall Clark, Speed, Safety, and Dignity: Pediatric Pharmaceutical Development in an Age of 
Optimism, 9 U. CHI. L. SCH. ROUNDTABLE 1, 44 (2002), reprinted in THE ETHICS AND REGULATIONS OF 
RESEARCH WITH HUMAN SUBJECTS 529 (2005).  
47 See Belmont Report, supra note 8, at 23,194. 
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relevant to medical research studies.48 The first discussion concerning the proper 
allocation of burdens and benefits of medical research studies appeared in the Belmont 
Report’s discussion of the justice principle.49 This report, mandated by the United 
States’ Congress, not only defined the term, but also provided the framework for 
which to apply the principle to medical research studies.50 Since 1986, when the 
Common Rule was enacted, the justice principle has been applied to all medical 
research funded by the federal government.51 Beginning in 1996, the justice principle 
was also applied to any medical research studies conducted outside the United States 
by a company seeking drug approval in the United States.52  
A. BELMONT REPORT 
In the early 1970s, the U.S. Senate Committee on Labor and Human Resources 
held hearings on some of America’s most egregious medical research studies, such as 
the Willowbrook study53 and the Tuskegee Syphilis study.54 As a result of the 
                                                 
48 Lederer & Grodin, supra note 4, at 3, 18-19. The precursor to international protections of human 
subjects participating in medical research studies was the Nuremberg Code in 1947, which was developed in 
response to the Trials of War Criminals before the Nuremberg Military Tribunals. See Nuremberg Code 
(1947), 313 BRIT. MED. J. 1448 (1996).  
49 Belmont Report, supra note 8, at 23,194. In fact, the justice principle was found only in the Belmont 
Report until 2000, when the World Medical Association added the principle to the Declaration of Helsinki, a 
renowned document of bioethics for medical research. See Robert V. Carlson, Kenneth M. Boyd & David J. 
Webb, The Revision and the Declaration of Helsinki: Past, Present, and Future, 57 BRITISH J. CLINICAL 
PHARMACOLOGY 695, 699-704 (outlining the 2000 revisions to the Decaration of Helsinki). For a discussion 
regarding the ethical documents that discuss the use of children in research trials, see Duane Alexander, 
Regulation of Research with Children: The Evolution from Exclusion to Inclusion, 6 J. HEALTH CARE L. & 
POL'Y 1, 1-3 (2002).  
50 Belmont Report, supra note 8, at 23,196-97. 
51 45 C.F.R. § 46.111(a)(3) (2015); Proposed Model Federal Policy for the Protection of Human 
Subjects, 51 Fed. Reg. 20,204 (June 3, 1986) (providing the opportunity for the public comment that 
provided the basis for the Common Rule); 53 Fed. Reg. 45,660 (Nov. 10, 1988) (recognizing that the 
response to public comment on 51 Fed. Reg. 20,204 led to the development of the Common Rule).  
52 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR 
REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, GUIDELINE FOR GOOD CLINICAL PRACTICE 1 
(1996) (providing “an international ethical and scientific quality standard for designing, conducting, 
recording and reporting trials that involve the participation of human subjects”).  
53 For fifteen years (1956-1971) researchers conducted a non-therapeutic medical research studies on 
children at the Willowbrook State School, an institutional facility for mentally ill children on Staten Island, 
New York. Carl Coleman, et al, Historical Antecedents: Medical Research in the United States from 1900 to 
the Early 1970s, in THE ETHICS AND REGULATIONS OF RESEARCH WITH HUMAN SUBJECTS 39 (2005). 
Researchers infected healthy children, thus the study was not to treat a disease from which the children 
suffered. Early in the study the children were fed “extracts of stools from [Hepatitis-]infected children” and 
injected with “more purified virus preparations” to determine “the natural history of hepatitis and the effects 
of gamma globulin in preventing or moderating its effects.” Id. While the study led researchers to develop a 
hepatitis vaccine and better understand the differences between Hepatitis A and B, healthy children were 
infected with life-long debilitating diseases. Id. The infected children could never use the new vaccine, and 
as a result of the studies were subject to costly treatment for the rest of their lives.  
The researchers defended their work by noting hepatitis “was prevalent in the institution.” Id. They 
assumed the children would eventually acquire the disease. Id. Major medical journals (the Journal of the 
American Medical Association and the New England Journal of Medicine) published the results of the study, 
commending the researchers for their use of vulnerable children. Id. (noting that Franz Inglefinger argued in 
the New England Journal of Medicine that “the children benefited from being infected under carefully 
controlled research conditions and receiving expert attention.”) Furthermore, many scholars argue that 
parental consent forms were not entirely voluntary as due to overcrowding, the only way to have a child 
admitted to Willowbrook was through the hepatitis study. Id.  
54 See Belmont Report, supra note 8, at 23,194. The Tuskegee Syphilis Study, conducted from 1932 
through 1972, denied economically disadvantaged African-American men access to standard treatment. See 
generally JAMES H. JONES, BAD BLOOD: THE TUSKEGEE SYPHILIS EXPERIMENT (1981). 
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hearings, Congress created the National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research (Commission).55 In addition, 
Congress imposed a moratorium on research conducted or supported by the U.S. 
Department of Health and Human Services (HHS) on a living human fetus56 until 
adequate protections for such subjects were developed.57  
The Belmont Report was an outgrowth of the Commission’s deliberations 
regarding ethical protections and a 1976 conference at the Smithsonian Institute’s 
Belmont Conference Center.58 In the Belmont Report, the Commission selected justice 
as one of the three fundamental ethical principles to protect vulnerable groups from 
exploitation in medical research studies.59 The Commission noted that in the United 
States the burden of participating in medical research studies was borne principally by 
the economically disadvantaged while the rich enjoyed the benefits, as evidenced by 
the Tuskegee Syphilis Study.60  
From 1932 until 1972, researchers enrolled economically disadvantaged black 
men in a study to document the course of syphilis, even though the course of the 
disease was already known.61 In exchange for free meals, medical exams and burial 
insurance, the researchers promised the men that they would provide treatment for 
their ‘bad blood,” which could include “anemic blood to muscle aches, general 
malaise, disorders such as parasitic infections, gonorrhea, syphilis, and other venereal 
disease.”62 The researchers never informed the men that they were participating in a 
medical research study, and therefore, never told them about the purpose of the 
study.63 Researchers also intentionally deprived these men of “demonstrably effective 
treatment in order not to interrupt the project, long after such treatment became 
generally available,” causing the unnecessary disability and death of the men, their 
wives, and their children.64 The study was not a therapeutic study because it was not 
                                                 
55 Belmont Report, supra note 8, at 23,192. The Commission was composed of eleven members 
appointed by the Secretary of HHS. Protection of Human Subjects of Biomedical and Behavioral Research 
Act, Pub. L. No. 93-348, § 201, 88 Stat. 348 (1974). The National Research Act advised the Secretary of 
HHS to choose the members of the Commission from distinguished individuals from the fields of medicine, 
law, ethics, theology, philosophy, humanities, health administration, government, public affairs, and the 
biological, physical, behavioral, and social sciences. Id. Five of the members of the Commission had to be 
individuals engaged in biomedical or behavioral research involving human subjects. Id. Members of the 
Commission included Dorothy I. Height, President of the National Council of Negro Women, Inc., Dr. 
Albert R. Jonsen, Associate Professor of Bioethics at the University of California at San Francisco, and 
Patricia King, Associate Professor of Law at Georgetown University Law Center. Office for Human 
Research Protections, The Belmont Report, HHS.GOV (March 15, 2016), http://www.hhs.gov/ohrp 
/regulations-and-policy/belmont-report/ [https://perma.cc/6665-WG3C].  
56 Prior to 1980 and the enactment of the National Research Act, the U.S. Department of Health and 
Human Services was originally named the U.S. Department of Health, Education, and Welfare. See 
Department of Education Organization Act, Pub. L. No. 96-88, § 509(e), 93 Stat. 695 (1979) (codified at 20 
U.S.C. § 3508 (2012). To avoid confusion when discussing events before and after the name change, I refer 
to the agency only as the U.S. Department of Health and Human Services. 
57 Pub. L. No. 93-348, § 213, 88 Stat. at 353.  
58 Belmont Report, supra note 8, at 23,192.  
59 Id. at 23,194. The two other principles were respect for persons and beneficence. These principles 
focus on ensuring that the subjects’ choices are voluntary (respect for persons) and that subjects are not 
sacrificed for the benefit of society (beneficence). Id. at 23,193-94. 
60 Id. at 23,194. 
61 JONES, supra note 54, at 4. 
62 WASHINGTON, supra note 1, at 164. 
63 See id. at 162-63. 
64 Belmont Report, supra note 8, at 23,194. See also Deleso Alford Washington, Examining the 
“Stick” of Accreditation for Medical Schools Through Reproductive Justice Lens: A Transformative Remedy 
For Teaching the Tuskegee Syphilis Study, 26 J. OF CIV. RIGHTS & ECON. DEV. 153, 177, 193 (2011). 
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testing a possible treatment of syphilis and blocked any access to treatment.65 
Additionally, the study was not a non-therapeutic study to attain generalizable 
knowledge because the medical community had already documented the disease 
process of syphilis.66 Thus, there was nothing gained from the study other than 
exploiting the economically disadvantaged and minorities. 
To put an end to the exploitation of the economically disadvantaged and 
minorities, the Commission incorporated social justice into the ethical principles 
governing medical research studies using human subjects.67 Specifically, the 
Commission created the justice principle to determine “Who ought to receive the 
benefits of research and bear its burdens?”68 To answer this question and establish the 
contours of the justice principle, the Commission defined what is just and what is 
unjust in the selection of research subjects.69  
In selecting research subjects, the justice principle requires that researchers ensure 
disadvantaged groups such as minorities, women, children, the institutionalized 
mentally infirm, prisoners, and the economically disadvantaged70 are not “being 
systematically selected simply because of their easy availability, their compromised 
position, or manipulability, rather than for reasons directly related to the problem 
being studied.”71 The Commission reasoned that: 
whenever research supported by public funds leads to the development of therapeutic 
devices and procedures, justice demands both that these not provide advantages only to 
those who can afford them and that such research should not unduly involve persons from 
groups unlikely to be among the beneficiaries of subsequent applications of the research.72  
According to the Commission, “the principle of justice gives rise to moral 
requirements that there be fair procedures and outcomes in the selection of research 
subjects” on two levels: Individual and Social.73 On the Individual level, researchers 
should include the disadvantaged in potentially beneficial research that is usually 
reserved for the rich, instead of using them for non-therapeutic and dangerous medical 
research studies.74 On the Social level, researchers must draw a distinction “between 
classes of subjects that ought, and ought not, to participate in any particular kind of 
research, based on the ability of members of that class to bear burdens and on the 
appropriateness of placing further burdens on [an already burdened group].”75 The 
Belmont Report noted that it was not fair for the economically disadvantaged, who rely 
on public funds for health care, to be considered as preferred research subjects for 
publicly funded research because of their need to access health care.76 Thus, there is an 
order of preference in the selection of research subjects, such that researchers should 
                                                 
65 See Washington, supra note 64, at 179-80. 
66 After a lawsuit was filed on July 23, 1973, the government settled the case for approximately $10 
million dollars ($37,500 to research participants with syphilis who were alive as of July 23, 1973, $15,000 to 
the heirs of research participants with syphilis, $16,000 to research participants without syphilis who were 
alive as of July 23, 1973, and $5,000 to the heirs of research participant without syphilis). JONES, supra note 
54, at 217-19. Researchers directly involved the study never apologized. Id.  
67 See Belmont Report, note 8, at 23,196.  
68 Id. at 23,194. 
69 See id. 
70 Id. at 23,193-34 and 23,196-97.  
71 Id. at 23,194.  
72 Id.  
73 Id. at 23,192. 
74 Id. at 23,196. 
75 Id. 
76 Id.  
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use the rich before the economically disadvantaged, the majority before minorities, and 
adults before children.  
On an Individual level, the justice principle requires inclusion of vulnerable 
groups for potentially beneficial research, while on a Social level this inclusion must 
be limited to protect vulnerable groups from being overburdened.77 Nevertheless, even 
after researchers balance the Individual and Social level requirements of the justice 
principle, the use of certain classes of people for research may be unjust because of 
“social, racial, sexual, and cultural biases institutionalized in society” that place a class 
of people in a vulnerable and compromised position, easily manipulated into 
participating in medical research studies.78  
For example, over three decades of empirical research studies show that racial 
bias institutionalized in society prevents many African Americans from receiving 
quality education, obtaining jobs, and accessing housing in safe, diverse, and 
environmentally-friendly neighborhoods.79 Studies show that African Americans 
seeking employment have a harder time obtaining employment because non-African 
American managers tend to hire more Caucasians.80 Also, African Americans with 
non-Caucasian names receive fifty percent less callbacks than African Americans with 
Caucasian sounding names.81 As a result, many African Americans are more likely to 
be unemployed or employed with no health insurance.82 Lacking health insurance or 
money to pay for health care, African Americans are left in a compromised position 
                                                 
77 See id. at 23,196. 
78 Id.  
79 See Martha E. Lang & Chloe E. Bird, Understanding and Addressing the Common Roots of Racial 
Health Disparities: The Case of Cardiovascular Disease and HIV/AIDS in African Americans, 25 HEALTH 
MATRIX 109, 121-24 (2015); Ruqaiijah Yearby, Sick and Tired of Being Sick and Tired: Putting an End to 
Separate and Unequal Health Care in the United States 50 Years After the Civil Rights Act of 1964, 25 
HEALTH MATRIX 1 (2015); Richard Delgado, Two Ways to Think About Race: Reflections on the Id, the 
Ego, and Other Reformist Theories of Equal Protection, 89 GEORGETOWN L.J. 2279 (2001); Andrew Grant-
Thomas & John A. Powell, Toward a Structural Racism Framework, 15 POVERTY & RACE 3 (2006); Ian F. 
Haney López, The Social Construction of Race: Some Observations on Illusion, Fabrication, and Choice, 29 
HARV. C.R.-C.L. L. REV. 1, 6–7, 11–17 (1994); Charles R. Lawrence III, The Id, the Ego, and Equal 
Protection: Reckoning with Unconscious Racism, 39 STANFORD L. REV. 317 (1989); Kimberle Crenshaw, 
Demarginalizing the Intersection of Race and Sex: A Black Feminist Critique of Antidiscrimination 
Doctrine, Feminist Theory and Antiracist Politics, U. CHI. L. FORUM 139, 139-140 (1989). These 
disadvantages affect the health of those that are disadvantaged. See Paula A. Braveman, Catherine Cubbin, 
Susan Egerter, David. R. Williams & Elsie Pamuk, Socioeconomic Disparities in Health in the United 
States: What the Patterns Tell Us, 100 AM. J. PUB. HEALTH S186, S186-89 (2010); Leith Mullings & Amy 
J. Schulz, Intersectionality and Health: An Introduction, in GENDER, RACE, CLASS, AND HEALTH 3, 12 
(Leith Mullings & Amy J. Schulz eds., 2006) (examining the different forms of isms that affect individuals 
health status); Pamela Braboy Jackson & David R. Williams, The Intersection of Race, Gender, and SES: 
Health Paradoxes, in GENDER, RACE, CLASS, AND HEALTH 131 (Leith Mullings & Amy J. Schulz eds., 
2006) (examining the affects of different statuses on health disparities); Ruth E. Zambrana & Bonnie 
Thornton Dill, Disparities in Latina Health: An Intersectional Analysis, in GENDER, RACE, CLASS, AND 
HEALTH 192 (Leith Mullings & Amy J. Schulz eds., 2006) (examining the affects of different statuses on 
health disparities); Peter Franks, Peter Muennig, Erica Lubetkin & Haomiao Jia, The Burden of Disease 
Associated With Being African-American in the United States and the Contribution of Socio-Economic 
Status, 62 SOC. SCI. & MED. 2469 (2006).  
80 Laura Giuliano, David I. Levine & Jonathan Leonard, Manager Race and the Race of New Hires, 27 
J. LAB. ECON. 589, 589-91, 598-603 (2009). 
81 Michael Luo, In Job Hunt, College Degree Can’t Close Racial Gap, N.Y. TIMES (Nov. 30, 2009), 
http://www.nytimes.com/2009/12/01/us/01race.html?_r=0; see also Marianne Bertrand & Sendhil 
Mullainathan, Are Emily and Greg More Employable Than Lakisha and Jamal? A Field Experiment on 
Labor Market Discrimination, 94 AM. ECON. REV. 991 (2004).  
82 Liz Hamel, Jamie Firth, and Mollyann Brodie, Kaiser Family Foundation/New York Times/CBS 
News Non-Employed Poll, KAISER FAMILY FOUND. (Dec. 11, 2014), http://kff.org/other/poll-finding/kaiser-
family-foundationnew-york-timescbs-news-non-employed-poll/ [https://perma.cc/B5R5-5CFA].  
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and easily manipulated into participating in medical research studies to obtain access 
to health care. Consequently, even if researchers fairly select African Americans as 
research subjects, without bad intent, these institutional racial biases, which place 
African Americans in a vulnerable and compromised position, easily manipulated into 
participating in medical research studies, make their use as research subjects a 
violation of the justice principle.83 To counteract these unjust social patterns the 
Belmont Report requires researchers to consider distributive justice in selecting 
research subjects and follow the order of preference, using the rich before the 
economically disadvantaged, the majority before minorities, and adults before 
children.84  
B. FEDERAL REGULATION OF MEDICAL RESEARCH STUDIES AND THE JUSTICE 
PRINCIPLE 
In 1986, the Belmont Report in its entirety, was adopted by sixteen federal 
agencies and departments, including HHS, and codified in 45 C.F.R Part 46 (the 
Common Rule).85 In fact, not only did the Common Rule make the justice principle 
law, but also it explicitly defined the groups protected by the justice principle as 
vulnerable populations that shall not be targeted.86 Vulnerable populations include 
minorities, children, prisoners, pregnant women, mentally disabled persons, and 
economically or educationally disadvantaged persons.87 It governs all research studies 
conducted by or funded by the federal government, except for those studies conducted 
in emergency settings.88  
Institutions receiving federal funding to conduct medical research must enter into 
a contractual agreement with the federal government, called an assurance, asserting 
that they will comply with the Common Rule.89 Once an institution’s assurance is 
approved and it receives federal funding, the federal government requires that all 
research conducted by the institution regardless of who funds it comply with 45 C.F.R 
Part 46. The Office for Human Research Protections (OHRP), a federal agency housed 
within HHS, is responsible for ensuring that institutions comply with their assurances 
and the Common Rule.90 To fulfill this task, OHRP may request additional information 
in writing, conduct telephone interviews, or conduct site visits.91 These visits can be 
random or in response to allegations of noncompliance with the Common Rule.92  
                                                 
83 See Belmont Report, supra note 8, at 23,196. 
84 Id.  
85 For list of agencies, see ROSS, supra note 10, at 23 n.101.  
86 45 C.F.R. § 46.111 (2015). 
87 Id.; see also Chapter 6 of INSTITUTIONAL REVIEW BOARD GUIDEBOOK, DEP’T OF HEALTH AND 
HUMAN SERVS., OFFICE FOR HUMAN RESEARCH PROT., http://archive.hhs.gov/ohrp/irb/irb_preface.htm 
[https://perma.cc/AYG9-6E3Q] [hereinafter OHRP GUIDEBOOK] (adding minorities to the list of vulnerable 
populations. See OHRP, Institutional Review Guidebook (1993) (on the file with the author) and available at 
http://www.hhs.gov/ohrp/compliance/index.html (last visited Feb. 5, 2016). 
88 Carl H. Coleman, Jerry A. Menikoff, Jesse A. Goldner & Nancy Neveloff Dubler, The Federal and 
State Regulatory Structure, in THE ETHICS AND REGULATIONS OF RESEARCH WITH HUMAN SUBJECTS 107 
(2005). 
89 See generally id. at 137 (discussing different types of assurances). 
90 Id.  
91 Coleman et al., supra note 88, at 136-37; see also Memorandum from Director to OHRP Staff (Dec. 
4, 2000), in THE ETHICS AND REGULATIONS OF RESEARCH WITH HUMAN SUBJECTS 138, 139 (2005) 
[hereinafter OHRP Memorandum]. For government funded medical research studies in which there has been 
an allegation of noncompliance, Office of Human Rights Protections’ (OHRP) initiates an investigation. Id. 
at 138-41. For a detailed sequence of events in compliance investigations, see id. at 140-41. 
92 Coleman et al., supra note 88, at 136-37. 
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When reviewing allegations of noncompliance, OHRP grants the institution an 
opportunity to refute the allegations.93 Once additional information is obtained, OHRP 
determines whether the institution has violated the law.94 OHRP issues corrective 
action for instances of noncompliance, which is in “the best interest of human research 
subjects, and to the extent possible, the institution, the research community, and 
HHS.”95 Corrective action may include restriction or withdrawal of approval for an 
institution’s assurance and suspension or permanent removal from participation in 
specific projects.96 Information regarding allegations and findings of noncompliance 
can be found on OHRP’s website.97 
OHRP is responsible for reviewing compliance at the institutional level.98 Every 
institution that has an assurance with OHRP is responsible for ensuring that individual 
medical research studies conducted by those affiliated with the institution comply with 
the Common Rule.99 To accomplish this task, all institutions and federal agencies that 
enter into an assurance with OHRP have an Institutional Review Board (IRB).100 There 
are an estimated 3,000 to 5,000 IRBs, which serve as the main protection for 
vulnerable populations in medical research studies.101  
Before researchers can conduct medical research studies using human subjects in 
the United States or be funded by the United States government to conduct medical 
research studies using human subjects, they must submit a research protocol to their 
IRB.102 A complete research protocol includes a statement of compliance with the 
ethical principles, such as the justice principle.103 The IRB reviews all written research 
protocols in application for medical research studies using human subjects to ensure 
that the proposed studies comply with the Common Rule, including the ethical 
requirements of the justice principle.104 If the IRB finds that the research protocol is 
ethical, they can approve the research to be conducted and/or submitted for funding to 
the United States government.105 The IRB can also require modifications in the 
research protocol or disapprove any research protocol.106 
                                                 
93 See OHRP Memorandum, supra note 91, at 139. 
94 Id. 
95 Id.  
96 Id. at 140. Many, including the former Secretary of HHS, have argued that regulatory agencies have 
failed to issue meaningful sanctions. See L. Song Richardson, When Human Experimentation Is Criminal, 
99 J. CRIM. L. AND CRIMINOLOGY 89, 126 (2008); Donna Shalala, Protecting Research Subjects – What 
Must Be Done, 343 NEW ENG. J. MED. 808 (2000). Usually, the only sanctions that OHRP imposes is 
posting a letter of violation on its website. See generally OHRP Determination Letters, DEP’T OF HEALTH 
AND HUMAN SERVS., OFFICE FOR HUMAN RESEARCH PROT., http://www.hhs.gov/ohrp/compliance-and-
reporting/determination-letters/index.html [https://perma.cc/9C4X-KR8V]. However, in the past when the 
public pressure has become too much, some institution have voluntarily stopped the research studies, while 
others have continued the reseach studies. See generally David B. Resnik, Research Ethics Timeline, NAT’L 
INSTS. OF HEALTH, http://www.niehs.nih.gov/research/resources/bioethics/timeline/ [https://perma.cc/LX68-
JKNP]. Yet, this is an erratic outcome that simply depends on how much media attention the study received. 
Id. 
97 See OHRP Determination Letters, supra note 96. 
98 45 C.F.R. § 46.103(a). 
99 Coleman et al., supra note 88, at 137.  
100 45 C.F.R. § 46.101(a)(2).  
101 Alison Wichman, Protecting Vulnerable Research Subjects: Practical Realities of Institutional 
Review Board Review and Approval, 1 J. HEALTH CARE L. AND POL’Y 88, 97 (1998). 
102 45 C.F.R. § 46.101(a)(2).  
103 45 C.F.R. § 46.103(b)(1). 
104 45 C.F.R. § 46.101(a)(2). 
105 See id.  
106 See 10 C.F.R. § 745.101; 45 C.F.R. § 46.101; 45 C.F.R. § 46.109(a).  
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In terms of the justice principle, the IRB is required to ensure that the “risks to 
subjects are minimized . . . by using procedures which are consistent with sound 
research design and which do not unnecessarily expose subjects to risk”107 and the 
selection of subjects is “equitable.”108 In order to determine if the selection of subjects 
is equitable the IRB is required to ensure that vulnerable populations are not targeted 
by taking into account the purposes of the research, the setting in which the research 
will be conducted, and the need to protect vulnerable populations.109 If the IRB allows 
vulnerable populations to be targeted, the institution is in violation of their assurance 
and subject to corrective action by OHRP. Not only does the justice principle apply to 
research conducted in the United States or funded by the United States government, 
but it also governs research used to seek drug approval in the United States.110 
C. ICH-GP 
The International Council for Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) “is a unique project . . . [that] 
brings together the regulatory authorities of Europe, Japan and the United States and 
experts from the pharmaceutical industry in the three regions to discuss scientific and 
technical aspects of product registration.”111 The sole purpose of ICH is “to make 
recommendations on ways to achieve greater harmonisation in the interpretation and 
application of technical guidelines and requirements for product registration in order to 
reduce or obviate the need to duplicate the testing carried out during the research and 
development of new medicines.”112 The ICH developed the Good Clinical Practice 
guidelines (GCP), “an international ethical and scientific quality standard for 
designing, conducting, recording and reporting [medical research] trials that involve 
the participation of human subjects.”113 Researchers generating medical research study 
data to be submitted to regulatory authorities in the EU, Japan, and the United States, 
must comply with the ICH-GCP in order to have their drug approved in these 
countries.  
Overall, “the objective of this ICH-GCP … is to provide a unified standard for the 
EU, Japan, and the United States to facilitate the mutual acceptance of clinical data by 
the regulatory authorities in these jurisdictions,” while protecting medical research 
subjects.114 Developed using ethical principles around the world to protect among 
other things, vulnerable populations from being targeted in medical research studies, 
the ICH-GCP defines vulnerable subjects as those who are economically 
disadvantaged, minority groups, and/or minors.115 To protect these vulnerable 
populations the ICH-GCP states that IRBs have to pay special attention to medical 
                                                 
107 45 C.F.R. 46.111(a)(1). 45 C.F.R. 46.111(a)(1). 
108 45 C.F.R. 46.111(a)(3). 45 C.F.R. 46.111(a)(3). 
109 Id. 
110 45 C.F.R. § 46.101(a).  
111 Value & Benefits, INT’L COUNCIL ON HARMONISATION http://www.ich.org/fileadmin/ 
Public_Web_Site/ABOUT_ICH/Vision/Value_Benefits_for_Industry_2000.pdf. 
112 Vision, INT’L COUNCIL ON HARMONISATION http://www.ich.org/about/vision.html 
[https://perma.cc/STF7-73C6].  
113 Good Clinical Practice: Consolidated Guidance, INT’L COUNCIL ON HARMONISATION 1 (1996), 
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073122.pdf [hereinafter Good Clinical Practice] 
114 Id.  
115 Id. at 7. The clinical guidelines came from countries and organizations including countries in the 
European Union, Japan, United States, Australia, Canada, the Nordic countries and the World Health 
Organization (WHO). Id. at 1. 
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research studies that include subjects from vulnerable populations.116 Additionally, the 
ICH-GCP incorporates all of the principles of the Declaration of Helsinki.117  
The Declaration of Helsinki, drafted and adopted in 1964 by the World Medical 
Association, is a statement of ethical standards that was designed as a guide to 
physicians and others participating in medical research studies involving human 
subjects, in addition to the responsibilities imposed by their own countries.118 In 2000, 
thirty-six years after the adoption of the document,119 the World Medical Association 
amended the Declaration of Helsinki to include the justice principle. 120  
Similar to the justice principle espoused in the Belmont Report, the Declaration of 
Helsinki advises medical researchers that vulnerable populations should not be 
targeted for medical research studies.121 Specifically, the Declaration of Helsinki states 
“[M]edical research with a vulnerable group is only justified if the research is 
responsive to the health needs or priorities of this group and the research cannot be 
carried out in a non-vulnerable group.”122 Hence, medical researchers cannot use 
human subjects from vulnerable populations just because they are readily available, 
easily manipulated into participating, or in a compromised position. Instead there is an 
order of preference in the selection of research subjects to use those from non-
vulnerable groups first.123 The incorporation of the justice principle into the ICH-GCP 
demonstrates clearly the importance of the principle in protecting research subjects 
across the world.  
Unfortunately, since the implementation of the justice principle in U.S. and 
international law, members of vulnerable populations continue to be targeted for 
medical research studies because of structural problems in the regulation process and a 
paradigm shift in the meaning of the justice principle. The regulatory problems, 
reasons for this shift, and examples of the egregious harm caused by both are discussed 
below. 
IV. PRIVATE REGULATION AND INCLUSION: BARRIERS TO 
ENFORCEMENT OF THE JUSTICE PRINCIPLE 
Structural flaws in the regulation of medical research studies have allowed 
researchers to often ignore the justice principle’s prohibition against targeting. 
Moreover, in 1990, only four years after being applied to medical research studies, 
there was a “paradigm shift” in the use of the justice principle that has allowed 
researchers to target economically disadvantaged minority children in the name of 
                                                 
116 Id. at 10.  
117 Id. at 1. 
118 See Declaration of Helsinki, supra note 3.  
119 The 2000 revision of the Declaration of Helsinki was the fifth revision to the document. Id. The 
document was revised in 1975, 1983, 1989, 1996, 2000, 2002, 2004, 2008, and 2013. Id. 
120 Carlson, supra note 49, at 699-704.  
121 See Declaration of Helsinki, supra note 3. Unlike the Common Rule, the Declaration of Helsinki 
does not define vulnerable populations using explicit characteristics. See id. Instead it states that “some 
groups and individuals are particularly vulnerable and may have an increased likelihood of being wronged or 
of incurring additional harm. All vulnerable groups and individuals should receive specifically considered 
protection.” Id. at Section 19. 
122 Id. at Section 20. The Declaration of Helsinki also requires that if vulnerable groups are used in 
medical research studies, the “group should stand to benefit from the knowledge, practices or interventions 
that result from the research.” Id. In addition, the Declaration states that “[i]n advance of a clinical trial, 
sponsors, researchers and host country governments should make provisions for post-trial access for all 
participants who still need an intervention identified as beneficial in the trial. This information must also be 
disclosed to participants during the informed consent process.” Id. at Section 34. 
123 See id. at Section 20. 
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inclusion.124 Specifically, instead of using the justice principle to protect economically 
disadvantaged minority children from researcher’s targeting, now researchers use the 
justice principle to grant economically disadvantaged minority children a ‘fair 
opportunity’ to participate in medical research studies.125 Proponents of inclusion have 
three main arguments. 
First, they argue that inclusion provides economically disadvantaged minority 
children with access to innovative drugs.126 This argument misapprehends the true 
meaning and nature of medical research. Medical research is not treatment and can be 
a dangerous endeavor that causes significant harm and death.127 Second, they argue 
that the justice principle kept vulnerable populations, such as economically 
disadvantaged minority children, from participating in medical research studies.128 
Empirical research shows that economically disadvantaged minority children never 
stopped participating in medical research studies.129 Third, proponents of inclusion 
argue that children are therapeutic orphans, meaning that they do not have drugs to 
address their specific health care needs, because the justice principle limits children’s 
participation in medical research studies.130 However, children have been therapeutic 
orphans since 1963, sixteen years before the creation of the justice principle.131 As a 
result of these regulatory and interpretation problems, economically disadvantaged 
minority children are still targeted for medical research studies. 
A. ENFORCEMENT FAILURES IN THE REGULATION OF MEDICAL RESEARCH STUDIES 
The current regulatory system is ineffective at protecting children from being 
targeted because the regulation of the justice principle has been left to the discretion of 
the very institutions that target vulnerable populations.132 The government delegated 
the authority to prevent targeting to IRBs, which are housed within the institutions that 
employ the researchers seeking grants.133 Because this money benefits the institution 
as well as the researcher, IRBs are often reluctant to deny approval of research 
protocols.134 
                                                 
124 Sarah H. Kiskaddon, Balancing Access to Participation in Research and Protection from Risks: 
Applying the Principles of Justice, J. NUTRITION 929, 931 (2005).  
125 Id. For more background regarding the conflict, see Michael Shevell, Ethics of Clinical Research in 
Children, 9 SEMINARS IN PEDIATRIC NEUROLOGY 46 (2002); Levine, supra note 14, at 116. 
126 Harold Varmus & David Satcher, Ethical Complexities of Conducting Research in Developing 
Countries, 337 NEW ENG. J. MED. 1003, 1003-04 (1997).  
127 The belief that medical research is treatment is called a “therapeutic misconception.” Oberman & 
Frader, supra note 6, at 308-10. 
128 Ross, supra note 10, at 51, 56. 
129 Id. 
130 STEVEN EPSTEIN, INCLUSION: THE POLITICS OF DIFFERENCE IN MEDICAL RESEARCH 63 (2007).  
131 See id. at 61. 
132 Donald Barlett & James Steele, Deadly Medicine, VANITY FAIR (Feb. 5, 2016), 
http://www.vanityfair.com/news/2011/01/deadly-medicine-201101 [http://perma.cc/4S8G-VFYG] (pointing 
out that independent contractors now run many drug medical research studies and select research subjects). 
Even though the same laws apply to these independent contractors and researchers from institutions with 
IRBs, the government does not even regulate these independent contractors. See id. Therefore, not only does 
the government need to regulate these contractors, but it should also apply the suggestions I have for 
preventing targeting discussed in Section V. 
133 For more discussion regarding the failures of IRBs, see Carl H. Coleman, Rationalizing Risk 
Assessment in Human Subject Research, 46 ARIZ. L. REV. 1 (2004); Hazel Glenn Beh, The Role of 
Institutional Review Board in Protecting Human Subjects: Are We Really Ready to Fix a Broken System?, 
26 L. & PSYCHOL. REV. 1, 34-41 (2002).  
134 Beh, supra note 133, at 34-41. 
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In fact, scholars have noted that IRBs often fail to comply with federal law 
because they are “too weak, overburdened, ignorant, or conflicted.”135 The failure of 
IRBs to comply with the law is particularly troubling in instances concerning the 
justice principle because the IRB is the main protector of the vulnerable against 
targeting by researchers. Data also suggests that IRBs rarely review protocols for 
compliance with the justice principle compared to other requirements such as 
autonomy (informed consent).136  
Empirical evidence shows that IRBs returned “only 10 percent of research 
proposals . . . to investigators for clarification of subject selection,” while IRBs 
returned “the consent portion of proposal . . . for correction 25 percent of the time.”137 
Moreover, if the proposed research subject is a pediatric patient in a hospital or clinic 
and a consenting parent or guardian is present, the researcher’s motives for including 
the child are never investigated.138 Additionally, the burdens borne by these children 
because of their socioeconomic and minority status are rarely measured.139 Thus, it is 
not surprising that some researchers continue to target economically disadvantaged 
minority children for use in medical research studies.  
Another reason for the persistent targeting of vulnerable populations is lax federal 
oversight. Scholars note that OHRP barely reviews IRB compliance with the Common 
Rule.140 Furthermore, there is no mandatory public reporting of medical research 
studies conducted in the United States or in foreign countries.141 Consequently, IRB 
decisions regarding the selection of research subjects are never disclosed to the public 
unless there are allegations made to OHRP or to the media that the Common Rule has 
been violated. Even if IRBs and the OHRP enforced the Common Rule, there would 
still be issues with research subject selection because the regulations and government 
guidance are devoid of meaningful practical advice on how to ensure that subjects are 
selected equitably according to the justice principle.142  
The OHRP issued an IRB Guidebook, a non-binding guidance to assist IRBs in 
fulfilling their responsibilities in protecting the rights and welfare of human 
subjects.143 Chapter VI of the Guidebook addresses special classes of subjects, which 
includes all of the groups listed in the vulnerable population definition in the Common 
Rule.144 Even though the Guidebook was issued in 1993, it is telling that the only 
discussion regarding the selection of subjects is in response to cognitively impaired 
persons.145 There is no discussion about the equitable selection of children or 
minorities, the main groups whose targeting served as the basis for the creation of the 
justice principle.146 Furthermore, even though the Guidebook addresses the use of 
children and foster children in medical research studies, these guidelines only focus on 
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autonomy (informed consent) and beneficence (the best interest of the child based on a 
benefit risk analysis), not the justice principle.147 
The lack of guidance in applying the justice principle is highlighted in the medical 
research literature. As T. Howard Stone notes, “[T]here is a dearth of literature 
addressing how IRBs should approach the review of research involving persons who 
are economically or educationally disadvantaged.”148 Consequently, persons from 
vulnerable populations “remain unduly vulnerable to clinical research risks, and they 
have become the ‘invisible vulnerable.’”149 These regulatory failures are compounded 
by the shift in interpretation of the justice principle from protection to inclusion.  
 
B. PROTECTION TO INCLUSION: THE PROBLEM OF INTERPRETATION 
The justice principle was only in effect for four years, when the federal 
government shifted its view from protection of vulnerable populations, to inclusion of 
vulnerable populations to promote greater access to medical research studies.150 This 
campaign to change the meaning of the justice principle was a result of three things: 1) 
HIV/AIDS epidemic; 2) the perceived lack of participation of economically 
disadvantaged minority children in medical research studies; and 3) the therapeutic 
orphan problem. In response to these three events, civil rights organizations, patients, 
physicians, and researchers began advocating for the right of vulnerable populations, 
particularly economically disadvantaged minority children, to participate in medical 
research studies to gain access to potentially life-saving treatment. Unfortunately, 
inclusion has not provided the benefits that advocates were fighting for. Instead, it has 
provided the justification for targeting economically disadvantaged minority children 
for participation in medical research studies. 
1. Therapeutic Misconception 
In the 1990s, medical research became synonymous with treatment. Carol Levine 
notes that the HIV/AIDS epidemic is responsible for the paradigm shift.151 As a result 
of the HIV/AIDS crisis, people were dying with no hope for treatment. New 
HIV/AIDS drugs and therapies were being tested in medical research studies, but not 
available to the general public. Consequently, HIV/AIDS medical research was viewed 
as “cutting-edge medical treatment” not “experimental research” that could cause 
serious harm.152 Thus, some HIV/AIDS activists began to argue that medical research 
“served as an important means of access to otherwise unobtainable and theoretically 
helpful new therapies.”153 In fact, some HIV/AIDS activists began to argue that access 
to medical research studies for vulnerable populations should be considered an 
essential good, like food and housing, rather than a risk from which vulnerable 
populations should be protected.154 However, these arguments misinterpret the true 
nature of medical research. 
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Medical research studies are not therapeutic and do not guarantee life-saving 
medicine. This is a therapeutic misconception.155 Although there is no potential for a 
benefit in Phase I and II medical research studies, many patients, providers, and even 
researchers believe that enrollment in these studies is beneficial for the patient because 
the patient will receive treatment.156 This therapeutic misconception is often used to 
justify the targeting of vulnerable populations to serve as research subjects, such as 
economically disadvantaged minority children, in medical research studies.157  
Participation in medical research studies is also not an essential good, like food, 
which economically disadvantaged minority children are often denied.158 Unlike an 
essential good, there are risks associated with participation in medical research studies 
including stigma, long-term disability, and death. For example, in the late 1980s, 
researchers in Los Angeles gave healthy African American infants five hundred times 
the approved dose of an experimental measles vaccine, which had already sickened 
and killed children in Senegal, Mexico, and Guinea-Bissau.159 Not only did this 
medical research study not provide any treatment, but it also caused harm. 
In the 1990s, the Kennedy Krieger Institute researchers investigating cheaper lead 
abatement techniques partnered with landlords to partially abate lead tainted housing 
in Baltimore.160 In order to test the efficacy of the abatement procedures, the 
researchers in collaboration with the landlords ensured that only families with healthy 
children lived in the lead tainted housing by agreeing to pay for abatement procedures 
if the landlords rented to families with young children.161 Due to the racial makeup of 
the neighborhood, the young children participating in the study were all minorities.162  
Even though the information given to parents “implied that the study was 
protecting their children from lead damage and promised to inform parents of any 
hazards,” such as abnormal tests showing high lead levels, the study was non-
therapeutic because it provided no benefit to the participants.163 In fact, the researchers 
did not notify the parents of their children’s elevated lead levels or lead hot spots in the 
house.164 As a result, many of the healthy children suffered exposure to lead, which 
can cause inattention, irritability, hyperactivity, learning and reading delays, delayed 
growth and hearing loss, permanent brain damage, and even death.165 Thus, this study 
did not provide treatment or a benefit to society, and it caused harm. 
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From 1992 to 1997, researchers at Columbia University’s Lowenstein Center for 
the Study and Prevention of Childhood Disruptive Behaviors and New York City’s 
New York State Psychiatric Institute conducted research to try to show a link between 
genetics and violence, using only healthy and non-violent African American and 
Latino children.166 The researchers administered fenfluramine to 126 boys between the 
ages of six and ten, even though the drug had already been shown to cause heart-valve 
damage, pulmonary hypertension (a life-threatening form of high blood pressure), 
brain damage, and death in adults.167  
As a result of participating in the study, children suffered physical harm including 
but not limited to anxiety, fatigue, headaches, lightheadedness, difficulty 
concentrating, visual impairment, diarrhea, and nausea.168 No generalizable knowledge 
was obtained from this study because the premise of the research was that genetics was 
linked with violence had been disproven by over a century of research.169 Furthermore, 
the researchers’ use of only minorities in the study, even though Caucasians also 
commit acts of violence, sent the message that minorities are more violent than 
Caucasians and thus must be studied.170 Thus, inclusion of minority children in the 
study did not grant them access to new medicine or treatment and it caused harm. 
These studies are not outliers. In fact, empirical data shows that in comparison 
with their percentage in the U.S. census, African American children continue to be 
overrepresented in non-therapeutic medical research studies and underrepresented in 
Phase III therapeutic medical research studies.171 This means that when compared to 
Caucasians, African American children participate in medical research studies that 
may not add to scientific knowledge beneficial to society, but not in medical research 
studies that will be beneficial for them as a group by providing treatment.  
Hence, the justice principle must mean more than a ‘fair opportunity’ for 
economically disadvantaged minority children to participate in medical research 
studies that are meaningless or can cause long-term disability or death. This holds true 
especially for economically disadvantaged minority children, who have already been 
denied the essential goods of food, housing, education, and access to health care. 
2. The Myth of Protection: Participation in Medical Research Studies Never Stopped  
In the 1990s HIV/AIDS disproportionately affected vulnerable populations 
allegedly protected from the harms of medical research (women, minorities, and 
children); these vulnerable populations, civil rights organizations, physicians, and 
researchers advocated for the populations’ right to participate in medical research 
studies to gain access to potentially life-saving treatment. The argument for the need 
for inclusion was further bolstered by media reports that minorities and children lacked 
access to HIV/AIDS drug studies.  
For example, using National Institutes of Health (NIH) documents, a reporter 
noted in a front page Los Angeles Times article that African Americans, Latinos, and 
groups disproportionately afflicted with HIV/AIDS were significantly 
underrepresented in federally-sponsored HIV/AIDS clinical trials.172 Advocates of 
inclusion also argued that children with HIV/AIDS in the United States did not receive 
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AZT until three years after adults gained access to AZT because children were denied 
participation in medical research studies as a result of the justice principle.173  
The theory of inclusion is based on an incorrect assumption that economically 
disadvantaged minority children were not participating in medical research studies, 
including those related to HIV/AIDS.174 However, even once the justice principle was 
adopted, economically disadvantaged minority children were being targeted for, and as 
a result, participating in medical research studies.  
For example as discussed in more detail in subsection C, economically 
disadvantaged healthy African American and Latino children in the United States and 
abroad were used as research subjects in Phase I and II HIV/AIDS drug studies.175 
Research shows that not only did some of these healthy children experience long-term 
disability or die as a result of their participation in these studies,176 but it also shows 
that many economically disadvantaged minority children in the United States and 
abroad still do not have access to this medicine.177  
Continuing lack of access to HIV/AIDS drugs is illustrated by a medical research 
study conducted by a U.S. researcher. Funded by the U.S. government, the research 
study used economically disadvantaged HIV-positive children in the Dominican 
Republic “to determine if massage therapy would boost the immune systems” of the 
children.178 “The children were ‘randomized’ into two groups. One received 
therapeutic massage; the other, made up of twelve HIV-positive children, met with a 
nurse for ‘reading, talking, playing quiet games’ as part of the friendly visit control 
group.”179 The results from the study were reported in The Journal of Alternative and 
Complementary Medicine.180 In this study, the inclusion doctrine was used to give 
economically disadvantaged minority children a ‘fair opportunity’ to participate in 
medical research studies that did not provide them with any access to HIV/AIDS 
drugs.181 The research did not address the problem of children as therapeutic 
orphans.182 Instead, it continued the practice of targeting minority children already 
living in poverty for medical research studies.183  
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3. Therapeutic Orphans  
In the 1990s, the federal government, health care providers, and parents were 
worried about the fact that children were ‘therapeutic orphans’ because “more that 75 
percent of drugs marketed [to children] in the United States” had never been tested in 
children.184 Arguing for the inclusion of children in medical research studies, “patient 
advocates and some clinicians have noted that, in the interest of good medical care, 
drugs should be tested on the populations that will use them.”185 Although this lack of 
testing is definitely a problem, the failure to test drugs on children was not a result of 
the four years of protection from targeting granted by the justice principle.  
Children have been ‘therapeutic orphans’ since 1963,186 at a time when 
researchers were putting radioactive material in healthy children’s oatmeal, cutting out 
parts of the brain of healthy children, injecting healthy children with Hepatitis, and 
using radiation to cause third-degree burns on healthy children as young as six months 
old.187 Hence, the therapeutic orphan problem was not a result of the protections 
required by the justice principle. It is not surprising that the shift to inclusion did not 
increase medical research studies using children. In fact even after the shift to 
inclusion, the U.S. government had to encourage pharmaceutical companies to conduct 
medical research studies on children.188 
In 1997, Congress passed the Food and Drug Administration Modernization Act 
(FDAMA) to incentivize pharmaceutical companies to conduct medical research on 
children by providing an additional six months of patent exclusivity to the companies 
even if the results were negative or inconclusive.189 The government hoped that the 
medical research would provide safety and efficacy information for drugs and 
therapies used on children, ensuring that they were no longer therapeutic orphans.190 In 
2000, Congress passed the Children’s Health Act, which included the Pediatric 
Research Initiative.191 The law made medical research studies of childhood illness and 
conditions a priority, however, funding for research using children still lagged behind 
funding for all other medical research.192 In 2002, Congress extended the FDAMA 
incentives in the Best Pharmaceuticals for Children Act (BPCA), which provided 
government subsidies for medical research studies testing drugs no longer under 
patent.193 A year later, Congress passed the Pediatric Research Equity Act, which 
requires that all new pharmaceuticals be tested on children.194  
Federal agencies and groups have also tried to increase the use of children in 
medical research studies. In 1998, the NIH issued policy guidelines requiring all NIH-
funded research to “include a plan for the inclusion of children, unless there is good 
justification to exclude them.”195 The Institute of Medicine (IOM) also issued a report 
about the use of children in medical research studies in response to a mandate in the 
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BPCA. The purpose of the IOM report was to increase the participation of children in 
medical research studies.196 Consequently, the IOM recommendations focused on 
access instead of protection including paying children to participate in medical 
research studies and permitting waivers of consent.197  
As a result of these efforts, between 1987 and 2006, 135 drugs were granted 
extended patent exclusivity and approximately 150 new drugs were approved through 
studies using children.198 Notwithstanding these incentives, children still remain 
therapeutic orphans. Pharmaceutical companies have focused on conducting medical 
research studies on children for drugs with a large adult market.199 Sometimes these 
studies have resulted in death or long-term disability. For example, in 2013, the U.S. 
Food and Drug Administration (FDA) halted all pediatric medical research studies of a 
calcium-lowering drug used in adults because of the death of a fourteen year old 
participating in the study.200 The drug was not geared to treat a childhood specific 
illness.201 Thus, inclusion of children in medical research studies has not fixed the 
therapeutic orphan problem.  
C. RESULTING HARM: TARGETING FOR INCLUSION 
Even when included in medical research studies conducted to find pediatric drug 
uses, many children are still targeted for medical research studies, resulting in serious 
harm. Below is a brief summary of the most notable studies.  
1. Studies in the United States 
For thirteen years (1988-2001), Illinois, Louisiana, Maryland, New York, North 
Carolina, Colorado, and Texas enrolled foster children, between the age of three 
months to nineteen years old, in Phase I and II drug studies for the treatment of the 
HIV/AIDS.202 Many of the foster children used for the study were African American 
or Latino and were economically disadvantaged.203 The studies were conducted to 
determine the drug toxicity and adverse side effects of drugs that had not been shown 
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to be safe in adults.204 Funded in part by the NIH, the trials exposed the drug toxicity 
and adverse side effects of potential HIV/AIDS drugs not yet proven to be safe for 
children.205 There were a plethora of problems with the studies, including the targeting 
of economically disadvantaged minority foster children because of their manipulability 
and compromised position.206  
In response to innumerable complaints and newspaper exposés, OHRP finally 
investigated the use of economically disadvantaged minority children in HIV/AIDS 
drug studies and found that their use was inequitable. Seventeen years after the 
HIV/AIDS drugs studies started, OHRP issued a letter to the head of the IRB at 
Columbia University Medical Center, noting that some of the HIV/AIDS drug studies 
conducted at their institution violated the law.207 Specifically, the IRB approved 
research protocols in which researchers had inequitably targeted economically 
disadvantaged minority children in foster care to participate in the studies.208 In 2006, 
OHRP sent letters of violation to fourteen other universities conducting HIV/AIDS 
drug studies.209 Each letter noted that the universities had targeted economically 
disadvantaged minority foster children in violation of the justice principle and the 
Common Rule.210  
Nevertheless, OHRP did not put an end to the studies, did not impose any 
sanctions, and its findings failed to directly address the actions of the researchers who 
violated the justice principle.211 Consequently, the researchers who conducted the 
studies were able to publish their findings in medical journals without repercussions. 
In issuing its findings, OHRP did not even explain why they found that the studies 
targeted economically disadvantaged minority children as research subjects, but I 
suggest several reasons. 
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First, the selection of the children for participation in the HIV/AIDS drug studies 
violated the justice principle’s order of preference for selecting subjects. The 
preference requires that adults are used before children, the rich before the 
economically disadvantaged, and the majority before the minority.212 Some of the 
drugs tested in children were simultaneously being tested in adults.213 Second, the 
children were public wards and according to the justice principle, researchers are not 
allowed to use the economically disadvantaged, who rely on public funds for health 
care, to be used as research subjects for publicly funded research.214 
Third, not all the children used in the HIV/AIDS drug studies were even tested for 
HIV/AIDS.215 The states gave blanket consent for the use of these children instead of 
reviewing the files of each child to see if the child was even infected with 
HIV/AIDS.216 Thus, it can be argued that the children were selected simply “because 
of their easy availability, their compromised position, or manipulability, rather than for 
reasons directly related to the problem being studied.”217  
Fourth, the healthy children were unnecessarily “exposed . . . to risks of medical 
research and drugs that were known to have serious side effects in adults and for which 
the safety for children was unknown.”218 The drugs tested were failed cancer drugs that 
had severe side effects including rashes, vomiting, sharp drops in infection-fighting 
blood cells, and death.219 Hence, yet again, healthy minority children were subjected to 
medical research studies that lead to disability and death.  
The dangers of participation in these studies for healthy children are best 
illustrated by an Illinois study of Dapsone, a drug to prevent AIDS-related 
pneumonia.220 “Researchers reported some children had to be taken off the drug 
because of ‘serious toxicity,’ others developed rashes, and the rates of death and blood 
toxicity were significantly higher in children who took the medicine daily, rather than 
weekly.”221 The researchers noted that for the period of the study “[a]t least 10 
children died from a variety of causes, including four from blood poisoning, and 
researchers said they were unable to determine a safe, useful dosage. They said the 
deaths didn’t appear to be ‘directly attributable’ to Dapsone but nonetheless were 
‘disturbing.’”222 
Finally, the HIV/AIDS drug studies continued even after 1990 when 
Azidothymidine, better known as AZT, was shown to be an effective treatment for 
HIV/AIDS without severe side effects.223 Children who participated in these 
HIV/AIDS drug tests were prohibited from taking AZT in order to determine if the 
new drugs were effective. This would have been acceptable if each foster child 
enrolled in the study had been tested to see if AZT was not an option. If AZT was not 
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an option for treatment, then and only then, would it be just for the children to 
participate in medical research.  
Advocates of the research have argued that the inclusion of these children in the 
research benefited the children by increasing their access to new and effective 
HIV/AIDS drugs.224 However, it is unclear how many children participating in the 
study actually needed access to HIV/AIDS drugs, because none of the children were 
actually tested for HIV/AIDS. .225 Furthermore, as discussed in Section IV.B.1, the 
presumption that participation in medical research studies, particularly Phase I and II 
studies, provides access to life-saving treatment is a therapeutic misconception. These 
phases only test safety and toxicity.226 Hence, participation in medical research studies 
at these stages does not provide the participant with a direct health benefit, especially 
when compared to the dangers of the research.  
Furthermore, economically disadvantaged minority children who have HIV/AIDS 
and participated in the early phases of HIV/AIDS drug studies were not provided with 
access to the drugs that were approved in the United States and abroad.227 In fact, 
many of these children with HIV/AIDS still do not have access to HIV/AIDS drugs 
because they cannot afford them.228 Harms caused by the inclusion doctrine are not 
just limited to the United States. Researchers have used this doctrine to grant 
economically disadvantaged minority children in developing countries a ‘fair 
opportunity’ to participate in medical research studies that have not increased access to 
treatment and have resulted in serious harm and death.229 
2. Inclusion Theory Internationally 
In 2008, researchers conducted vaccine trials on infants in Santiago del Estero, a 
province of Argentina.230 The trials were testing Synflorix, a new vaccine, “to prevent 
pneumonia, ear infections, and other pneumococcal diseases,” which would compete 
against a vaccine already approved and proven safe and effective.231 That year, seven 
babies died from Synflorix, and a total of fourteen children died during the testing.232 
Because there was no evidence that children in this region disproportionately suffered 
from ailments Synflorix was intended to treat, there was no reason to use these 
children for the study other than their compromised position and easy manipulability. 
Over a thirty-month period, children in New Delhi were enrolled in medical 
research studies testing a wide range of drugs “from high blood pressure to chronic 
focal encephalitis, a brain inflammation that causes epileptic seizures and other 
neurological problems.”233 Approximately, two-thirds of the children studied were less 
than one year old, of which forty-nine died as a result of participation in these medical 
research studies.234 Again there was no evidence that children in this region 
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disproportionately suffered from these conditions, so there was no reason to use them 
for the study other than their compromised position and easy manipulability. 
In 1996, researchers traveled to Kano, Nigeria to test Trovan, an antibiotic, on 
pediatric patients suffering from bacterial meningitis.235 The objective of the study was 
to determine whether an oral version of Trovan, one of the United States’ best selling 
antibiotics, worked better than ceftriaxone, a fast-acting antibiotic already proven 
effective for treating bacterial meningitis.236 Two hundred children waiting for 
ceftriaxone, the proven therapy, participated in the study.237 Instead of receiving 
ceftriaxone, some children were given an oral version of Trovan, which had never 
been tested before in humans.238 Others were given a dose of ceftriaxone that was 
below the dosage prescribed to treat bacterial meningitis.239 Eleven children died 
unnecessarily.240 Advocates of the research and the inclusion doctrine argued that the 
research did not violate the justice principle because it provided access to medicine as 
“a ‘massive epidemic [of bacterial meningitis] killing more than 11,000 people’” 
spread across Nigeria.241 However, this study inequitably targeted Nigerian children in 
violation of the justice principle.  
Comparable to the HIV/AIDS drug studies discussed above, the antibiotic medical 
research studies violated the order of preference for selecting research subjects because 
children were used to test oral Trovan before being proven safe in humans.242 Second, 
the study was conducted during an epidemic although there was already a proven 
treatment.243 Thus, it can be argued that the children were selected because the 
bacterial meningitis was an epidemic, which put the children in a compromised 
position to participate in medical research studies that promised potentially life-saving 
treatment.244 
Third, the study caused harm because it prevented all participants from obtaining 
the proven therapy. Even though some children were given ceftriaxone, the dosage 
was below that needed to treat bacterial meningitis.245 Moreover, the oral form of 
Trovan was never used outside of the study and three years later the United States 
limited the use of the non-oral form of Trovan because it was linked to liver damage 
and deaths.246  
As evidenced by the aforementioned studies, the inclusion doctrine has been used 
as a justification for ignoring the requirements of the justice principle to target 
economically disadvantaged minority children for participation in medical research. 
The time has come to redefine justice, to measure the impact of research on vulnerable 
populations, and to implement a new regulatory structure for approving medical 
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research studies conducted using children, particularly economically disadvantaged 
minority children. 
V. JUSTICE AS EQUITY IN PARTICIPATION: USING THE VULNERABILITY 
AND EQUITY IMPACT ASSESSMENT TO STOP TARGETING 
Although arguments for inclusion were based on altruistic notions of providing 
everyone with a ‘fair opportunity’ to participate in medical studies, some researchers 
have used this interpretation of the justice principle to target economically 
disadvantaged minority children. As a result, numerous children have died or been 
seriously harmed. Consequently, the justice principle must be redefined in a manner 
that ensures equity and fairness in the use of all children.  
I suggest that justice should be defined as “equity in participation,” which 
demands that economically disadvantaged minority children are only selected for 
medical research studies if their participation allows them to reach their highest 
attainable standard of health, by granting them continued access to health care and/or 
the alleviation of some burdens placed on them. This is accomplished when the 
medical research study focuses on conditions that are a priority to this population, 
eliminates some social disadvantage, and does not place additional burdens on them. 
To ensure that there is equity in participation in medical research studies using 
economically disadvantaged minority children, I propose the use of the Vulnerability 
and Equity Impact Assessment (VEIA), which I created based on the Health Equity 
Impact Assessment (HEIA) tool.247 Under the VEIA, the researcher must complete an 
introspective summary of their research that includes the study’s purpose, the affected 
population, whether the research is a priority to the affected population, and any 
disparities (age, race, or class) in the treatment of the condition. Researchers must also 
identify the social disadvantage of, and burdens on, these vulnerable children being 
considered for participation, the adverse impacts from participating in the study, and 
how participation will outweigh these burdens and adverse impacts. If researchers 
determine that because of their status (age, social class, or race) children are easily 
manipulated, in a compromised position, or overburdened, then the researchers cannot 
use the children as research subjects.  
Using the VEIA, a newly created Board of Children (Board) would be responsible 
for approving all medical research studies that include children and are seeking federal 
funding or drug approval in the United States. The completed tool should be posted on 
ClinicalTrials.gov and used by the Board to determine if the researcher is targeting 
economically disadvantaged minority children in violation of the redefined justice 
principle. Redefining justice to mean equity in participation, implementing the VEIA, 
and creating a Board to review all medical research studies using children will provide 
the analytical and regulatory framework currently missing from the IRB process. 
A. JUSTICE AS EQUITY IN PARTICIPATION 
To put an end to targeting, there must be a shift in the interpretation of the justice 
principle from the inclusion doctrine to the “equity in participation” doctrine, which I 
created based on equity in health definitions.248 The justice principle should include a 
definition of equity, which requires that everyone have a fair opportunity to attain his 
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or her full health potential,249 instead of having a fair opportunity to participate in 
medical research studies.  
Specifically, equity in participation will require researchers to use the order of 
preference to select research subjects and prevent them from overburdening 
economically disadvantaged minority children by further restricting their limited 
access to health care. Hence, I propose that the justice principle be defined as equity in 
participation based on Drs. Braveman and Gruskin’s definition of equity in health. 
Braverman and Gruskin’s definition states that, “[e]quity in health is an ethical 
value, inherently normative, [and] grounded in the ethical principle of distributive 
justice.”250 Equity in health has been used to “guide operationalization and 
measurement” of the right to the “highest attainable standard of health as indicated by 
health status of the most socially advantaged group.”251 According to Drs. Braveman 
and Griskin, equity in health is “the absence of systematic disparities in health (or in 
the major social determinants of health) between [race and class] social groups who 
have different levels of underlying social advantage/disadvantage—that is different 
positions in a social hierarchy.”252 “Inequities in health systematically put groups of 
people who are already socially disadvantaged (for example, by virtue of being 
economically disadvantaged, female, and/or members of a disenfranchised racial, 
ethnic, or religious group) at further disadvantage with respect to their health.”253 “The 
concept of health equity focuses attention on the distribution of resources and other 
processes that drive a particular kind of health inequity.”254 “A health disparity 
between more and less advantaged population groups constitutes an inequity . . . 
because the disparity is strongly associated with unjust social structures,” which “put 
disadvantaged groups at generally increased risk of ill health and also generally 
compound the social and economic consequences of ill health.”255  
Not only does equity define what is fair, it imposes duties. According to the 
government of Ontario, equity in health requires the state to reduce “systemic barriers 
to equitable access to high quality health care for all; [to address] the specific health 
needs of people all along the social gradient, including the most health disadvantaged 
populations; and [to ensure] that the ways in which health services are provided and 
organized contributes to reducing overall health disparities.”256 Health equity also 
imposes a duty on the state to work to “reduce or eliminate socially structured health 
inequalities and differential health outcomes.”257 
Using these theories of equity and duty as a guide, I suggest that the justice 
principle be defined in terms of equity in participation. In particular, equity in 
participation should mean that vulnerable populations, such as economically 
disadvantaged minority children, can only serve as research subjects when the medical 
research study will allow the participants to reach their highest attainable standard of 
health. This is accomplished when the medical research focuses on conditions that are 
a priority to the vulnerable population, eliminates some form of social disadvantage, 
                                                 
249Susan Povall et al, Health Equity Impact Assessment, 29 HEALTHY PROMOTION INT’L 621, 622 
(2013).  
250 Braveman & Gruskin, supra note 248, at 256.  
251 Id. at 254. 
252 Id. 
253 Id.  
254 Id. at 255. 
255 Id.  
256 ONTARIO MINISTRY OF HEALTH AND LONG-TERM CARE, Workbook: Using the Health Equity 
Impact Assessment Tool 3 (2009).  
257 Id. 
MISSING THE “TARGET”: PREVENTING THE UNJUST INCLUSION OF 
VULNERABLE CHILDREN FOR MEDICAL RESEARCH STUDIES 
 
 
825 
and does not add burdens to the vulnerable population. Even if the study fulfills these 
requirements, researchers should not use these populations if they are in a 
compromised position and participation can exacerbate the problems that these 
vulnerable populations experience because of their race, class, and age.  
For example, institutionalized class and racial biases predict differential access to 
essential goods, such as health care, which cause disparities in disease, disability, and 
death.258 Burdened by an increase in disease, disability, and death, these children are a 
panacea for researchers investigating treatment and obtaining generalizable scientific 
knowledge, not usually relevant to their health condition.259 Powerless these children 
are invited to participate in medical research studies that provide minimal access to 
health care and will not alleviate their increased rate of disease, disability, or death.260 
By doing this, researchers perpetuate the continued unequal distribution of access to 
health care when they use those without access for studies not even focused on issues 
suffered by their children.  
Under the equity in participation doctrine, researchers would not be able to take 
advantage of the fact that economically disadvantaged minority children lack access to 
health care, as a means to enroll them in medical research studies. The researchers 
could only use them as subjects if the study focused on issues that are a priority to 
economically disadvantaged minority children and eliminated some social 
disadvantage, like lack of access to health care. To measure whether the equity in 
participation requirement is being met, I suggest that researchers be required to use 
VEIA.261  
B. HEALTH IMPACT ASSESSMENT TOOLS 
In 1970, the United States became the first country to require impact assessments 
to predict and assess the impact of policies on environmental health.262 Since then, 
several countries (Germany, Switzerland, and Canada) and international organizations 
(World Health Organization and the European Union) have required Environmental 
Impact Assessments to be completed in response to “highways, train lines, airports, 
industrial plants, waste disposal facilities, and many other development projects.”263 
Since 1999, many countries, such as Germany, Switzerland, the Netherlands, 
Australia, New Zealand, Canada, and the United States have adopted this tool for use 
in the health field to avoid or minimize negative impacts on health.264 Impact 
assessment tools put the burden on those researchers completing the tool to show that 
their actions will not negatively impact the health of the population. 
The Health Impact Assessment (HIA) is “a combination of procedures, methods 
and tools by which a policy, programme or project may be judged as to its potential 
effects on the health of a population, and the distribution of those effects within the 
population.”265 There are two main functions of the HIA: 1) “to support policy making 
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in choosing between options” and 2) to predict “the future consequences” of 
implementing different policy options.266 There are six key stages in using a HIA: 
“screening, scoping, data collection, impact appraisal, reporting/recommendations, and 
monitoring/evaluation.”267 By using the HIA, policymakers can adopt the most 
beneficial policy for the population’s health. Attaining equity in health can be one of 
the priorities in completing an HIA. However, equity is not the main focus of the 
HIA.268 Although the HIA can determine if the policy will have different impacts on 
different social groups, the process does not provide information concerning whether 
these differential impacts are a result of unfair and biased policies.269  
Consequently, the HEIA was created to ensure that assessments about a policy’s 
impact would include an evaluation of fairness and equity as well as root causes of 
inequities.270 The HEIA identifies the root causes of health inequity, such as wealth, 
income, knowledge, and power imbalances.271 The World Health Organization’s 
Commission on the Social Determinants of Health has recommended the use of the 
HEIA in all global, national, and local policy making.272 New Zealand, Australia, 
Canada, the United Kingdom, the United States, and other countries currently use the 
HEIA.273 There are five purposes of a HEIA: 
x Help identify potential health impacts (positive or negative) of a plan, policy or 
program on vulnerable or disadvantaged groups within the general population. 
x Help develop recommendations as to what adjustments to the initiative might 
mitigate negative impacts as well as maximize positive impacts on the health of 
vulnerable or disadvantaged groups.  
x Embed equity across an organization’s existing and prospective decision-
making models, so that it becomes a core value and one criterion to be weighed 
in all decisions.  
x Support equity-based improvement in program/service design: ‘How does this 
program need to be adjusted to meet the needs of specific populations?’ ‘Could 
this program benefit some, but not others?’ 
x Raise awareness about health equity as a catalyst for change throughout the 
organization, so planners and managers develop ‘stretch goals’: How can we 
include more people in this program, especially those often missed? What 
barriers do we have to look for? Are we as effective as we could be, especially 
those with the greatest and most complex health needs?274 
When completing a HEIA, the following five steps must be completed: 
Screening: 
Determine if the initiative requires a HEIA. If the initiative has the potential to impact the 
health of vulnerable or disadvantaged groups, HEIA is applicable. It is desirable that all 
initiatives be screened.  
Scoping:  
Identify affected populations or groups and predict key impacts (positive or negative) on 
those groups. Consider a wide range of vulnerable or disadvantaged groups to avoid 
overlooking unexpected or unintended consequences of an initiative.  
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Impact Assessment:  
Use available data/evidence to prospectively assess the impacts on vulnerable or 
disadvantaged groups in relation to the broader target population. It is both useful and 
important to consider a broader range of evidence including consultation findings and grey 
literature (including project or program reports, informal practice guidelines, recommended 
or promising practices). These sources of evidence should be weighed based on their 
strength and quality.  
Where there is very limited data/evidence available, note the lack of evidence in the 
assessment or, where possible, implement other strategies to gather evidence. Strategies 
could include conducting surveys, focus groups, or consultation with experts or members 
of the affected groups where time permits.  
Mitigation Strategy  
Develop evidence-based recommendations to minimize or eliminate negative impacts and 
maximize positive impacts on vulnerable or disadvantaged groups. These 
recommendations comprise your mitigation strategy. Uptake of these recommendations in 
the roll out of the initiative will help to ensure that the initiative contributes to equity and 
does not perpetuate or widen existing health disparities. Where possible, recommendations 
should be informed by diverse members of the affected communities.  
Monitoring and Evaluation  
Determine how the rollout of the initiative will be monitored to determine its impacts on 
vulnerable or disadvantaged groups in comparison to other subpopulations or the broader 
target population. The resulting data will enhance the overall evidence base for equity-
based interventions and can be fed back into the planning, policy or program development 
process.275 
Once these steps have been completed, the organization must decide whether or 
not to implement the policy.276  
A Racial Equity Impact Assessment (REIA) tool has also been created to identify 
the impacts of policies on racial and ethnic groups.277 Governments in Seattle, 
Washington, St. Paul, Minnesota, and the United Kingdom have adopted the REIA.278 
Although the primary focus of the HEIA and REIA are to reduce health inequities, I 
believe that with some modification these tools can be used to create a tool to address 
inequities in medical research, such as the targeting of economically disadvantaged 
minority children.  
C. VULNERABILITY AND EQUITY IMPACT ASSESSMENT TOOL 
Based in part on the HEIA and the REIA, the VEIA should be used to assess 
whether a proposed research study is targeting vulnerable populations for use in 
medical research in violation of the redefined justice principle. The VEIA would 
require researchers to review the “social, racial, sexual, and cultural biases 
institutionalized in society” that place a class of people in a compromised position and 
easily manipulated into participation in medical research studies. The VEIA will 
require researchers to identify these institutionalized biases and determine whether the 
problems from these biases bar vulnerable populations from participating in medical 
research studies because it keeps them from attaining their highest standard of health. 
In this article I focus on how the VEIA can be used to protect disadvantaged children; 
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however, the VEIA can be used to protect all children and other vulnerable 
populations.279 
1. The VEIA 
First, the researcher must screen the research proposal to identify the purpose of 
the research, what the research seeks to accomplish, and whether the research has the 
potential to negatively affect economically disadvantaged minority children. If the 
research has a potential to burden this population or prevent them from attaining their 
highest standard of health, the researcher must discuss in their research proposal, why 
they feel that the use of these vulnerable children is necessary. Additionally, the 
researcher must discuss whether the research is a priority for the children. This review 
can be incorporated into the current requirement of showing that research will add to 
generalizable scientific knowledge.280 
In order to answer these questions, the researcher must engage economically 
disadvantaged minority children or someone who represents their interests, such as 
Marian Wright Edelman, the President and Founder of the Children’s Defense Fund,281 
or community leaders who focus on children’s health issues. This screening dovetails 
with procedures used by researchers when they conduct international research to 
ensure that research is culturally competent.282 Once this introspective review, or 
screening, has occurred and is noted in the research proposal, then the researcher must 
complete the scoping, impact assessment, and mitigation strategy steps.  
To complete the scoping step, the researcher must answer the following questions: 
 
1. What populations are most affected by the condition being studied? 
2. Even if economically disadvantaged minority children are most affected 
by the condition, are there other less vulnerable populations that can be 
used for the research? 
 
If economically disadvantaged minority children are most affected by the 
condition, then the researcher must assess whether the impacts on this population are 
negative or positive. To complete the impact assessment step, a researcher must use all 
available data, such as empirical research studies. If there is limited data available, 
then the researcher should collect data by “conducting surveys, focus groups, or 
consultation[s] with experts or members of the affected groups where time permits.”283 
The evidence should be used to answer the following questions: 
 
1. Disparities: 
a. Are there race, class, and/or age disparities in the number of people 
who suffer from the condition? 
b. Are there race and/or class disparities in the number of people who 
survive the condition? 
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c.  “What quantitative and qualitative evidence of inequality exists?” 284 
d. Which racial/ethnic groups are currently most advantaged and most 
disadvantaged by the issues this research seeks to address? 
e. Which socioeconomic groups are currently most advantaged and 
most disadvantaged by the issues this research seeks to address? 
f. Which age groups are currently most advantaged and most 
disadvantaged by the issues this research seeks to address? 
g. How are groups affected differently?  
h. What evidence is missing or needed? 
i. Will the research exacerbate these disparities? 
j. Will the research address these disparities? 
2. Burdens: 
a. What are the burdens on economically disadvantaged minority 
children who are potential research subjects? 
b. Will participation in medical research studies exacerbate these 
burdens?  
c. What are the root causes of the burdens, such as racial and class 
biases? 
d. Will the research address these root causes? 
3. Adverse Impacts: 
a. What potential adverse impacts or unintended consequences could 
result from participation in this research?  
b. Will the impacts or unintended consequences further burden 
economically disadvantaged minority children? 
c. How could adverse impacts be prevented or minimized? 
d. Can the research provide a solution to address the burdens faced by 
economically disadvantaged minority children?  
4. “Equitable Impacts: 
a. What positive impacts on equality and inclusion, if any, could result 
from this proposal?  
b. Which racial/ethnic groups could benefit?  
c. Which socioeconomic groups could benefit?  
d. Which age groups could benefit?  
e. Are there further ways to maximize equitable opportunities and 
impacts?” 285 
 
Using the answers from these questions, the researcher must provide an evidence-
based determination of whether economically disadvantaged minority children should 
be used as subjects because there are no additional burdens and/or the research will 
eliminate burdens for this population. If the researcher decides to use economically 
disadvantaged minority children as research subjects even though there is a possibility 
for targeting, the researcher must develop a mitigation strategy that will minimize or 
eliminate the institutionalized biases that prevent economically disadvantaged minority 
children from equal access to essential goods such as food, education, and health care. 
If there is a mitigation strategy, the researcher must monitor the strategy throughout 
the study. Additionally, once the research is conducted, the researcher must monitor 
the actual impact the research has on economically disadvantaged minority children in 
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comparison to advantaged groups. One way to monitor the impact is to determine 
whether there is a decrease in survival rate disparities between economically 
disadvantaged minority children and the advantaged population once the research is 
conducted.  
2. Applying the VEIA 
If researchers are required to apply the VEIA, many of the studies that targeted 
vulnerable populations in violation of the law would never have been funded.  
For example, if the researchers who used African American and Latino foster 
children to test HIV/AIDS drugs, completed a VEIA, the tool would have shown the 
research violated the justice principle. First, the researchers would have been required 
to screen the research to identify the purpose of the research, what the research sought 
to accomplish, and whether the research had the potential to affect economically 
disadvantaged minority children.  
Clearly, the screening would have shown that the medical research study had the 
potential to impact economically disadvantaged minority children if they were used as 
subjects, and it is unclear why healthy children had to be used to test HIV/AIDS drugs. 
Furthermore, there is no evidence that this research was a priority to healthy 
vulnerable children in foster care. If researchers were able to show that HIV/AIDS was 
a health priority, the research would still be prohibited under the scoping step. There is 
no evidence that at the time of the research, economically disadvantaged African 
American and Latino children were the group most affected by HIV/AIDS. Therefore, 
other children should have been used. Moreover, the impact assessment would have 
shown that the research was too dangerous to conduct on this population because the 
drugs had severe side effects for otherwise healthy children.  
Additionally, the researchers discussed in Section IV.C.2 who traveled to Nigeria 
to test Trovan on pediatric patients suffering from bacterial meningitis would not have 
been able to show that their study complied with the justice principle using the 
VEIA.286 If researchers had screened the study, VEIA would have shown that the 
Nigerian children, who were vulnerable, would be negatively impacted by the 
research. The scoping step would have shown that other children were also affected by 
bacterial meningitis. Because these other groups were not in the middle of an 
epidemic, they would have been better subjects.  
Furthermore, VEIA would have shown that the negative impact of the research 
outweighed any benefits from participation in the medical research study and could not 
be mitigated. First, there was already a proven therapy for the disease that children 
participating in the study were barred from taking.287 Second, the children could have 
died, an unreasonable impact that cannot be mitigated by any benefit. Thus, the 
researchers never should have used economically disadvantaged minority children. 
These are just a couple of examples of how using the VEIA will protect 
economically disadvantaged minority children from being targeted. However, the 
adoption of justice as equity in participation and implementation of the VEIA will not 
put an end to targeting without changes to the current regulatory structure governing 
medical research studies using children.  
D. A NEW REGULATORY STRUCTURE 
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In the past, OHRP and individual IRBs have been responsible for ascertaining 
whether the selection of economically disadvantaged minority children violated the 
justice principle. The examples discussed in Section I.V.C. suggest that neither OHRP, 
nor individual IRBs have been successful in accomplishing this task. Thus, I suggest 
the creation of a federal Human Research Protection Review Board for Children 
(Board for Children or the Board) using the authority granted by the Common Rule to 
review medical research studies otherwise unapprovable288 and the creation of an 
International Board of Children (IBOC) to review medical research studies using the 
authority granted by the w.  
The Board for Children and the IBOC would be in charge of determining whether 
domestic and international medical research studies involving children were ethically 
based upon the redefined justice principle.289 Before a medical research study was 
conducted the Board of Children and/or the IBOC would be required to review the 
research proposal to evaluate whether the research targets economically disadvantaged 
minority children for studies in violation of the redefined justice principle.  
To accomplish this task for research governed by the Common Rule, the Board for 
Children needs to have adequate community participation and specific requirements 
for the approval of research. The Board for Children must include at least two 
members of each group identified as a vulnerable population in the Common Rule. 
The Board for Children must also consist of at least two physicians that conduct 
research. However, these physicians cannot be from institutions that have been cited 
for violations by the OHRP. Finally, the Board for Children should include three 
bioethicists, two child advocates, and two government employees. 
The Board must review the VEIA for all medical research studies using children 
governed by the Common Rule to ensure the studies comply with the redefined justice 
principle. This review must occur before the researcher submits the proposal for 
funding and drug approval. The Board would be responsible for reviewing the VEIA 
for each research proposal to make sure that the study was not targeting economically 
disadvantaged minority children for medical research studies.290 If the VEIA shows 
that there is no targeting and the study was necessary and safe, then the Board should 
approve the study and post the VEIA on ClinicalTrials.gov. 
The IBOC should review proposals for medical research studies using children 
that are governed by the ICH-GCP. Using the VEIA to enforce the ICH-GCP, the 
IBOC would review all proposals for pediatric studies to ensure they comply with the 
redefined justice principle. The membership of the IBOC would include members of 
each group identified as a vulnerable population group in the ICH-GP. The IBOC 
would also consist of at least two physicians that conduct research. However, these 
physicians cannot be private contractors or from organizations that have conducted 
illegal and unethical research in the past. Finally, the IBOC should include three 
bioethicists, two child advocates, and three government employees (one from each 
regulatory authority in the EU, Japan, and the United States). The IBOC’s review 
would be the similar to the Board of Children’s review. The review would take place 
before the researcher submits the proposal for drug approval.  
Specifically, if a researcher planned to seek drug approval under the ICH-GCP, 
the researcher would need to complete a VEIA and submit it to the IBOC before 
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conducting studies on children. The IBOC would review the VEIA for each research 
proposal and ensure that the study was not unfairly targeting economically 
disadvantaged minority children for medical research.291 If the VEIA shows that there 
is no targeting and the study was necessary and safe, then the IBOC should approve 
the study. 
The creation of these Boards is just the beginning of the structural changes that 
need to be made to regulate pediatric medical research. Additionally, new penalties 
need to be imposed if a researcher and/or an institution violates the justice principle. 
Currently, OHRP just issues letters and suspends researchers from federally-funded 
research. Violations of the justice principle should also result in fines, loss of federal 
funding, and denial of drug approval. Researchers that violate the requirements should 
also face criminal fines.292 Furthermore, victims of research conducted in violation of 
the justice principle should be granted a private right of action against the institution 
and the researcher.  
As more and more pediatric research is conducted overseas and outside of the 
public eye, it is imperative that the U.S. government, in cooperation with other 
governments, begins to aggressively enforce laws to protect all children, especially 
economically disadvantaged minority children, from being targeted for participation in 
medical research. Otherwise, these children will continue to suffer long-term disability 
or death.  
VI. CONCLUSION 
Children are vulnerable beings who we try to protect by limiting their access to 
alcohol, guns, and employment.293 Moreover, we limit their autonomy because, 
although we believe children are sacred, we question their decision-making capacity. 
We impose these limitations seemingly to protect children because they are vulnerable 
and susceptible to exploitation.294 Yet, some researchers willingly exploit children by 
targeting them to participate in medical research studies because it has the potential to 
benefit society.  
Some bioethicists and researchers argue that all children are morally required to 
participate in medical research studies to provide a benefit to the society that benefits 
them. However, for economically disadvantaged minority children who lack access to 
essential goods, one must ask what benefit are the children receiving that they need to 
pay back? For many countries, including the United States, do not provide, nor 
guarantee a right to food, education, housing or health care for these children. So what 
duty do these children have to society? This is not a new question. As Patricia King 
noted, “American bioethics has tended to focus its attention on ethical issues 
associated with scientific and medical advances without recognizing that these 
developments occur in a social context that must be taken into account if the ethical 
issues are to be adequately addressed.”295 
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Therefore, the time has come to put an end to this exploitation by enforcing the 
justice principle and prevent the targeting of all children, but especially economically 
disadvantaged minority children, from participation in medical research studies. This 
will only happen if the justice principle stands for more than inclusion. The justice 
principle must be a measurable standard that ensures fairness, equity, and the right of 
children to reach their full health potential without interference. Otherwise, children 
will continue to be sacrificed for the benefit of an unworthy society. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
